Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma and breast cancers, among others.

Pharmaceutical

Olatec Therapeutics

Olatec Therapeutics' headquarters in New York, NY, United States

Damaris B. Skouras

Sophia Hughes

Piscitelli Philip

Jeanette Rooney, CPA, CGMA

Cynthia (Dana) Barrow

Charles A. Dinarello

Robert H. Dworkin

Steven B. Newhard

Shayne C. Gad

Leo A. B. Joosten

Howard I. Maibach

Alberto Mantovani

F. Kip Vought

Timotheus Jansen

Jose Ángel Cordova Villalobos

Matthijs Janssen

Antonio Abbate

William J. Cunningham

Robert M. Fielding

Lucio C. Rovati

Gregory K. Palm

Craig T. Basson

Spyros S. Skouras, Jr.

Valentín Campos, Sr.

John F. Otto

George A. Skouras

Andrea Leonard-Segal

Peter Libby

Viola T. Kung

Marc J. Philippon

Amy K. Poshusta

Daniel Yadegar

Description

People (3)

Damaris B. Skouras

Jeanette Rooney, CPA, CGMA

Sophia Hughes

Jobs